Antibody-decorated chitosan-iodoacetamide-coated nanocarriers for the potential delivery of doxorubicin to breast cancer cells.

0579973 - ÚOCHB 2025 RIV NL eng J - Článek v odborném periodiku
Myat, Y. Y. - Sahatsapan, Nitjawan - Rojanarata, T. - Ngawhirunpat, T. - Opanasopit, P. - Pornpitchanarong, C. - Patrojanasophon, P.
Antibody-decorated chitosan-iodoacetamide-coated nanocarriers for the potential delivery of doxorubicin to breast cancer cells.
International Journal of Biological Macromolecules. Roč. 258, č. 1 (2024), s. 128797. ISSN 0141-8130. E-ISSN 1879-0003
Institucionální podpora: RVO:61388963
Klíčová slova: tumor targeting * trastuzumab * chitosan-iodoacetamide * nanocarriers * doxorubicin
Impakt faktor: 8.2, rok: 2022
Způsob publikování: Omezený přístup
https://doi.org/10.1016/j.ijbiomac.2023.128797

Using an active targeting approach of chemotherapeutics-loaded nanocarriers (NCs) with monoclonal antibodies is a potential strategy to improve the specificity of the delivery systems and reduce adverse reactions of chemotherapeutic drugs. Specific targeting of the human epidermal growth factor receptor-2 (HER-2), expressed excessively in HER-2-positive breast cancer cells, can be achieved by conjugating NCs with an anti-HER-2 monoclonal antibody. We constructed trastuzumab-conjugated chitosan iodoacetamide-coated NCs containing doxorubicin (Tras-Dox-CHI-IA-NCs) as a tumor-targeted drug delivery system, during the study. Chitosan-iodoacetamide (CHI-IA) was synthesized and utilized to prepare trastuzumab-conjugated NCs (Tras-NCs). The morphology, physicochemical properties, drug loading, drug release, and biological activities of the NCs were elucidated. The Tras-NCs were spherical, with a particle size of approximately 76nm, and had a positive zeta potential, after incorporating the drug, the size of the Tras-NC increased. A prolonged, 24-h drug release from the NCs was achieved. The Tras-NCs exhibited high cellular accumulation and significantly higher antitumor activity against HER-2-positive breast cancer cells than the unconjugated NCs and the drug solution. Therefore, Tras-Dox-CHI-IA-NCs could be a promising nanocarrier for HER-2-positive breast cancer.
Trvalý link: https://hdl.handle.net/11104/0348764